Fibrin chain cross-linking, fibrinolysis, and in vivo sealing efficacy of differently structured fibrin sealants.
In this study, we compared the sealing characteristics and efficacy of a fibrin sealant with reduced plasminogen (FS-rplg) and a fibrin sealant with aprotinin as a fibrinolysis inhibitor (FS-apr). The relevant sealing characteristics including clot structure, fibrin chain cross-linking, and clot lysis were tested in the laboratory. The sealing efficacy was then investigated in a follow-up animal model to determine differences in the in vivo sealing properties. A total of 46 animals were available for the final analysis with 23 animals in each treatment arm. In conclusion, we saw differences in vitro between FS-rplg and FS-apr in ultrastructure and α-chain cross-linking rates as well as in the rate of fibrinolysis. These differences may explain the significantly enhanced sealing efficacy in FS-apr compared to FS-rplg shown in vivo in a rabbit intestinal model.
Baxter Innovations GmbH, Biosurgery Division Industriestrasse 131, A-1220 Vienna, Austria.
Hans Christian
HC
Hedrich
Manuela
M
Simunek
Sonja
S
Reisinger
James
J
Ferguson
Heinz
H
Gulle
Andreas
A
Goppelt
Heinz
H
Redl
D000818:Animals; D007611:Aprotinin / Q000493:pharmacokinetics / Q000494:pharmacology*; D005337:Fibrin / Q000493:pharmacokinetics / Q000494:pharmacology*; D015718:Fibrin Tissue Adhesive / Q000493:pharmacokinetics / Q000494:pharmacology*; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D008422:Materials Testing; D010958:Plasminogen / Q000493:pharmacokinetics / Q000494:pharmacology*; D011817:Rabbits; D015842:Serine Proteinase Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology*; D014014:Tissue Adhesives / Q000493:pharmacokinetics / Q000494:pharmacology*
D015718:Fibrin Tissue Adhesive; D005343:Fibrinolytic Agents; D015842:Serine Proteinase Inhibitors; D014014:Tissue Adhesives; D005337:Fibrin; D010958:Plasminogen; D007611:Aprotinin